Stem definition | Drug id | CAS RN |
---|---|---|
histamine-H2-receptor antagonists, cimetidine derivatives | 1129 | 76824-35-6 |
Dose | Unit | Route |
---|---|---|
40 | mg | O |
40 | mg | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 67 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.98 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 42 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 6.60 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.84 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.80 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 15, 1986 | FDA | VALEANT PHARMS NORTH |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective | 431.28 | 9.60 | 797 | 118168 | 818536 | 49667623 |
Contraindicated product administered | 276.27 | 9.60 | 19 | 118946 | 148939 | 50337220 |
Synovitis | 266.21 | 9.60 | 5 | 118960 | 123860 | 50362299 |
Drug intolerance | 251.89 | 9.60 | 100 | 118865 | 219004 | 50267155 |
Hand deformity | 200.71 | 9.60 | 8 | 118957 | 100191 | 50385968 |
Joint swelling | 198.47 | 9.60 | 171 | 118794 | 245115 | 50241044 |
Systemic lupus erythematosus | 188.37 | 9.60 | 49 | 118916 | 140573 | 50345586 |
Glossodynia | 182.60 | 9.60 | 27 | 118938 | 115542 | 50370617 |
Treatment failure | 180.51 | 9.60 | 50 | 118915 | 137587 | 50348572 |
Arthropathy | 170.33 | 9.60 | 79 | 118886 | 157827 | 50328332 |
Therapeutic product effect decreased | 170.08 | 9.60 | 54 | 118911 | 135996 | 50350163 |
Rheumatoid arthritis | 165.26 | 9.60 | 140 | 118825 | 202410 | 50283749 |
Hepatic function abnormal | 132.72 | 9.60 | 259 | 118706 | 32422 | 50453737 |
Pneumonia aspiration | 127.48 | 9.60 | 247 | 118718 | 30757 | 50455402 |
Pericarditis | 122.86 | 9.60 | 19 | 118946 | 78670 | 50407489 |
Wound | 121.91 | 9.60 | 48 | 118917 | 105746 | 50380413 |
Gastrooesophageal reflux disease | 115.70 | 9.60 | 419 | 118546 | 76009 | 50410150 |
Platelet count decreased | 110.05 | 9.60 | 499 | 118466 | 100227 | 50385932 |
White blood cell count decreased | 109.96 | 9.60 | 554 | 118411 | 116168 | 50369991 |
Lower respiratory tract infection | 108.37 | 9.60 | 44 | 118921 | 95157 | 50391002 |
Maternal exposure during pregnancy | 106.88 | 9.60 | 131 | 118834 | 159647 | 50326512 |
Alopecia | 98.85 | 9.60 | 274 | 118691 | 244773 | 50241386 |
Chronic kidney disease | 97.49 | 9.60 | 258 | 118707 | 39513 | 50446646 |
Off label use | 88.57 | 9.60 | 703 | 118262 | 473723 | 50012436 |
Helicobacter infection | 87.44 | 9.60 | 8 | 118957 | 49694 | 50436465 |
Duodenal ulcer perforation | 86.94 | 9.60 | 5 | 118960 | 45606 | 50440553 |
Toxicity to various agents | 85.38 | 9.60 | 238 | 118727 | 212261 | 50273898 |
Hepatic enzyme increased | 83.34 | 9.60 | 121 | 118844 | 137259 | 50348900 |
Drug abuse | 81.73 | 9.60 | 20 | 118945 | 59826 | 50426333 |
Swelling | 76.29 | 9.60 | 231 | 118734 | 200641 | 50285518 |
Discomfort | 75.50 | 9.60 | 86 | 118879 | 108294 | 50377865 |
Musculoskeletal stiffness | 73.28 | 9.60 | 118 | 118847 | 128363 | 50357796 |
Disseminated intravascular coagulation | 72.25 | 9.60 | 138 | 118827 | 16997 | 50469162 |
Folliculitis | 69.85 | 9.60 | 6 | 118959 | 39219 | 50446940 |
Product use issue | 69.69 | 9.60 | 155 | 118810 | 149320 | 50336839 |
Arthralgia | 69.04 | 9.60 | 679 | 118286 | 438023 | 50048136 |
General physical health deterioration | 68.64 | 9.60 | 145 | 118820 | 142289 | 50343870 |
Aspartate aminotransferase increased | 68.41 | 9.60 | 363 | 118602 | 77635 | 50408524 |
Abdominal discomfort | 66.55 | 9.60 | 299 | 118666 | 231342 | 50254817 |
Neutrophil count decreased | 59.47 | 9.60 | 240 | 118725 | 45786 | 50440373 |
Flushing | 55.45 | 9.60 | 307 | 118658 | 66708 | 50419451 |
Dehydration | 54.95 | 9.60 | 574 | 118391 | 151875 | 50334284 |
Cholecystitis chronic | 53.87 | 9.60 | 88 | 118877 | 9581 | 50476578 |
Alanine aminotransferase increased | 53.19 | 9.60 | 373 | 118592 | 87986 | 50398173 |
Liver disorder | 52.89 | 9.60 | 200 | 118765 | 37022 | 50449137 |
Therapeutic product effect incomplete | 52.21 | 9.60 | 84 | 118881 | 91431 | 50394728 |
Ill-defined disorder | 52.04 | 9.60 | 32 | 118933 | 54622 | 50431537 |
Pain | 51.77 | 9.60 | 1005 | 117960 | 577898 | 49908261 |
Blood lactate dehydrogenase increased | 51.11 | 9.60 | 130 | 118835 | 19432 | 50466727 |
Drug hypersensitivity | 48.53 | 9.60 | 368 | 118597 | 250642 | 50235517 |
Angioedema | 45.94 | 9.60 | 193 | 118772 | 37483 | 50448676 |
Interstitial lung disease | 45.60 | 9.60 | 246 | 118719 | 52930 | 50433229 |
Knee arthroplasty | 41.71 | 9.60 | 16 | 118949 | 35830 | 50450329 |
Mobility decreased | 41.40 | 9.60 | 78 | 118887 | 79870 | 50406289 |
Butterfly rash | 40.63 | 9.60 | 29 | 118936 | 1207 | 50484952 |
Upper respiratory tract inflammation | 40.27 | 9.60 | 38 | 118927 | 2351 | 50483808 |
Chest discomfort | 39.19 | 9.60 | 361 | 118604 | 92361 | 50393798 |
Hepatocellular injury | 38.86 | 9.60 | 7 | 118958 | 25940 | 50460219 |
Anaphylactic reaction | 38.47 | 9.60 | 238 | 118727 | 53817 | 50432342 |
Enterocolitis | 36.90 | 9.60 | 60 | 118905 | 6507 | 50479652 |
Impaired healing | 36.21 | 9.60 | 68 | 118897 | 69718 | 50416441 |
Completed suicide | 36.19 | 9.60 | 173 | 118792 | 131716 | 50354443 |
Cerebral infarction | 34.85 | 9.60 | 121 | 118844 | 21483 | 50464676 |
Diarrhoea | 34.79 | 9.60 | 1703 | 117262 | 586773 | 49899386 |
Urticaria | 34.75 | 9.60 | 461 | 118504 | 129100 | 50357059 |
Urinary tract infection | 34.53 | 9.60 | 728 | 118237 | 223292 | 50262867 |
Torsade de pointes | 34.47 | 9.60 | 82 | 118883 | 11753 | 50474406 |
Plasma cell myeloma | 33.29 | 9.60 | 154 | 118811 | 31168 | 50454991 |
Sopor | 32.91 | 9.60 | 4 | 118961 | 19875 | 50466284 |
Red blood cell sedimentation rate increased | 32.80 | 9.60 | 14 | 118951 | 29402 | 50456757 |
Gallbladder disorder | 31.69 | 9.60 | 99 | 118866 | 16643 | 50469516 |
Mental status changes | 30.55 | 9.60 | 167 | 118798 | 36105 | 50450054 |
Constipation | 30.08 | 9.60 | 608 | 118357 | 185100 | 50301059 |
Periorbital oedema | 29.81 | 9.60 | 47 | 118918 | 4965 | 50481194 |
Decreased appetite | 29.36 | 9.60 | 648 | 118317 | 200275 | 50285884 |
Exposure during pregnancy | 29.12 | 9.60 | 166 | 118799 | 120849 | 50365310 |
Pneumonia | 28.96 | 9.60 | 1125 | 117840 | 377276 | 50108883 |
Psoriatic arthropathy | 28.91 | 9.60 | 41 | 118924 | 46991 | 50439168 |
Infective pulmonary exacerbation of cystic fibrosis | 28.89 | 9.60 | 60 | 118905 | 7849 | 50478310 |
Hip arthroplasty | 28.71 | 9.60 | 18 | 118947 | 30411 | 50455748 |
Lip swelling | 28.07 | 9.60 | 124 | 118841 | 24612 | 50461547 |
Loss of personal independence in daily activities | 26.95 | 9.60 | 80 | 118885 | 69970 | 50416189 |
Gastrointestinal disorder | 26.43 | 9.60 | 123 | 118842 | 94333 | 50391826 |
Blood alkaline phosphatase increased | 25.31 | 9.60 | 163 | 118802 | 37363 | 50448796 |
Acute respiratory failure | 25.25 | 9.60 | 134 | 118831 | 28648 | 50457511 |
Overdose | 24.97 | 9.60 | 135 | 118830 | 99592 | 50386567 |
Drug resistance | 24.68 | 9.60 | 7 | 118958 | 18982 | 50467177 |
Haemorrhage subcutaneous | 24.51 | 9.60 | 31 | 118934 | 2670 | 50483489 |
Irritable bowel syndrome | 24.23 | 9.60 | 53 | 118912 | 51388 | 50434771 |
Hypoxia | 24.15 | 9.60 | 204 | 118761 | 50919 | 50435240 |
Febrile neutropenia | 23.93 | 9.60 | 342 | 118623 | 97325 | 50388834 |
Coma | 22.79 | 9.60 | 219 | 118746 | 56660 | 50429499 |
End stage renal disease | 22.71 | 9.60 | 45 | 118920 | 5692 | 50480467 |
Dizziness | 22.44 | 9.60 | 1012 | 117953 | 345357 | 50140802 |
Pyrexia | 22.32 | 9.60 | 1100 | 117865 | 379103 | 50107056 |
Nausea | 21.76 | 9.60 | 1932 | 117033 | 703466 | 49782693 |
Lymphocyte stimulation test positive | 21.71 | 9.60 | 14 | 118951 | 492 | 50485667 |
Neuropathy peripheral | 21.44 | 9.60 | 333 | 118632 | 96424 | 50389735 |
Blister | 21.18 | 9.60 | 116 | 118849 | 85302 | 50400857 |
Chest pain | 21.14 | 9.60 | 555 | 118410 | 176327 | 50309832 |
Somnolence | 21.11 | 9.60 | 495 | 118470 | 154490 | 50331669 |
Ventricular tachycardia | 20.83 | 9.60 | 83 | 118882 | 15738 | 50470421 |
Fibromyalgia | 20.64 | 9.60 | 47 | 118918 | 44931 | 50441228 |
Basophil count decreased | 20.38 | 9.60 | 8 | 118957 | 93 | 50486066 |
Renal injury | 20.22 | 9.60 | 55 | 118910 | 8556 | 50477603 |
Sepsis | 20.13 | 9.60 | 431 | 118534 | 132494 | 50353665 |
Rheumatoid nodule | 20.04 | 9.60 | 3 | 118962 | 12732 | 50473427 |
Foetal exposure during pregnancy | 19.82 | 9.60 | 21 | 118944 | 27338 | 50458821 |
Biliary dyskinesia | 19.63 | 9.60 | 27 | 118938 | 2523 | 50483636 |
Blood potassium decreased | 19.38 | 9.60 | 151 | 118814 | 36794 | 50449365 |
Palmar erythema | 19.28 | 9.60 | 21 | 118944 | 1542 | 50484617 |
Throat tightness | 18.93 | 9.60 | 98 | 118867 | 20749 | 50465410 |
Drug eruption | 18.76 | 9.60 | 107 | 118858 | 23499 | 50462660 |
Blood bilirubin increased | 18.53 | 9.60 | 134 | 118831 | 31904 | 50454255 |
Blood pressure fluctuation | 18.49 | 9.60 | 35 | 118930 | 35788 | 50450371 |
Acquired haemophilia | 18.44 | 9.60 | 16 | 118949 | 887 | 50485272 |
Hereditary angioedema | 18.40 | 9.60 | 40 | 118925 | 5402 | 50480757 |
Cholecystitis acute | 18.33 | 9.60 | 47 | 118918 | 7059 | 50479100 |
Hospice care | 17.91 | 9.60 | 41 | 118924 | 5731 | 50480428 |
Dermatitis atopic | 17.80 | 9.60 | 31 | 118934 | 3555 | 50482604 |
Cystitis noninfective | 17.80 | 9.60 | 15 | 118950 | 799 | 50485360 |
Throat irritation | 17.80 | 9.60 | 127 | 118838 | 30112 | 50456047 |
Anaphylactoid reaction | 17.64 | 9.60 | 30 | 118935 | 3376 | 50482783 |
Condition aggravated | 17.58 | 9.60 | 548 | 118417 | 296510 | 50189649 |
Hepatotoxicity | 17.47 | 9.60 | 23 | 118942 | 27203 | 50458956 |
Abdominal distension | 17.34 | 9.60 | 254 | 118711 | 72649 | 50413510 |
Arthritis | 17.26 | 9.60 | 126 | 118839 | 86595 | 50399564 |
Weight increased | 17.18 | 9.60 | 353 | 118612 | 201538 | 50284621 |
Premature baby | 17.09 | 9.60 | 11 | 118954 | 18326 | 50467833 |
Hypokalaemia | 16.96 | 9.60 | 296 | 118669 | 87696 | 50398463 |
Asteatosis | 16.94 | 9.60 | 6 | 118959 | 51 | 50486108 |
Respiratory alkalosis | 16.93 | 9.60 | 25 | 118940 | 2494 | 50483665 |
Rebound acid hypersecretion | 16.89 | 9.60 | 10 | 118955 | 301 | 50485858 |
Dyspnoea | 16.86 | 9.60 | 1500 | 117465 | 546108 | 49940051 |
Serotonin syndrome | 16.78 | 9.60 | 20 | 118945 | 24693 | 50461466 |
Atrioventricular block complete | 16.70 | 9.60 | 46 | 118919 | 7209 | 50478950 |
Intentional product use issue | 16.67 | 9.60 | 109 | 118856 | 76809 | 50409350 |
Erythema multiforme | 16.66 | 9.60 | 53 | 118912 | 8997 | 50477162 |
White blood cell count increased | 16.61 | 9.60 | 162 | 118803 | 42078 | 50444081 |
Injection site reaction | 16.58 | 9.60 | 61 | 118904 | 49971 | 50436188 |
Injection site pain | 16.48 | 9.60 | 174 | 118791 | 110850 | 50375309 |
COVID-19 | 16.45 | 9.60 | 175 | 118790 | 46487 | 50439672 |
Injection site bruising | 16.41 | 9.60 | 39 | 118926 | 36729 | 50449430 |
Medication error | 16.35 | 9.60 | 38 | 118927 | 36066 | 50450093 |
Cytokine release syndrome | 16.29 | 9.60 | 51 | 118914 | 8583 | 50477576 |
Infection | 16.05 | 9.60 | 298 | 118667 | 172656 | 50313503 |
Protein total decreased | 15.94 | 9.60 | 37 | 118928 | 5219 | 50480940 |
Blood magnesium decreased | 15.87 | 9.60 | 60 | 118905 | 11100 | 50475059 |
Contusion | 15.78 | 9.60 | 178 | 118787 | 112005 | 50374154 |
Lupus hepatitis | 15.76 | 9.60 | 5 | 118960 | 29 | 50486130 |
Therapy non-responder | 15.76 | 9.60 | 64 | 118901 | 50958 | 50435201 |
Full blood count decreased | 15.65 | 9.60 | 98 | 118867 | 22248 | 50463911 |
Disease progression | 15.54 | 9.60 | 314 | 118651 | 95552 | 50390607 |
Anaemia | 15.33 | 9.60 | 733 | 118232 | 251723 | 50234436 |
Gallbladder injury | 15.30 | 9.60 | 17 | 118948 | 1277 | 50484882 |
Cholelithiasis | 15.11 | 9.60 | 146 | 118819 | 37827 | 50448332 |
Cholinergic syndrome | 15 | 9.60 | 10 | 118955 | 372 | 50485787 |
Congenital neuropathy | 14.96 | 9.60 | 4 | 118961 | 11 | 50486148 |
Deep vein thrombosis | 14.63 | 9.60 | 248 | 118717 | 73056 | 50413103 |
Hyperuricaemia | 14.25 | 9.60 | 33 | 118932 | 4647 | 50481512 |
Small intestinal obstruction | 14.22 | 9.60 | 75 | 118890 | 15993 | 50470166 |
Nasopharyngitis | 14.22 | 9.60 | 345 | 118620 | 192582 | 50293577 |
Gastritis | 14.22 | 9.60 | 129 | 118836 | 32854 | 50453305 |
Reversible cerebral vasoconstriction syndrome | 14.20 | 9.60 | 21 | 118944 | 2098 | 50484061 |
Haematocrit decreased | 14.17 | 9.60 | 135 | 118830 | 34841 | 50451318 |
Device expulsion | 14.15 | 9.60 | 29 | 118936 | 28793 | 50457366 |
Chills | 14.15 | 9.60 | 312 | 118653 | 96375 | 50389784 |
Device difficult to use | 14.10 | 9.60 | 3 | 118962 | 9883 | 50476276 |
Amino acid level decreased | 14.07 | 9.60 | 5 | 118960 | 43 | 50486116 |
Swelling face | 14.02 | 9.60 | 187 | 118778 | 52408 | 50433751 |
Ileus | 14.02 | 9.60 | 65 | 118900 | 13164 | 50472995 |
Hypoalbuminaemia | 14.02 | 9.60 | 53 | 118912 | 9807 | 50476352 |
Asthma | 13.95 | 9.60 | 291 | 118674 | 89046 | 50397113 |
Liver injury | 13.92 | 9.60 | 23 | 118942 | 24783 | 50461376 |
Red blood cell count decreased | 13.91 | 9.60 | 131 | 118834 | 33704 | 50452455 |
Blood urea increased | 13.85 | 9.60 | 99 | 118866 | 23486 | 50462673 |
Musculoskeletal pain | 13.83 | 9.60 | 106 | 118859 | 72071 | 50414088 |
Burkholderia test positive | 13.78 | 9.60 | 8 | 118957 | 232 | 50485927 |
Cytomegalovirus enterocolitis | 13.52 | 9.60 | 11 | 118954 | 558 | 50485601 |
Therapeutic response decreased | 13.51 | 9.60 | 61 | 118904 | 47170 | 50438989 |
Dyspepsia | 13.48 | 9.60 | 247 | 118718 | 73850 | 50412309 |
Tubulointerstitial nephritis | 13.46 | 9.60 | 71 | 118894 | 15140 | 50471019 |
Hypervolaemia | 13.25 | 9.60 | 104 | 118861 | 25395 | 50460764 |
Vomiting | 13.24 | 9.60 | 1256 | 117709 | 459502 | 50026657 |
Pyuria | 13.23 | 9.60 | 18 | 118947 | 1665 | 50484494 |
Hypoparathyroidism | 13.10 | 9.60 | 11 | 118954 | 583 | 50485576 |
Victim of chemical submission | 13.10 | 9.60 | 8 | 118957 | 255 | 50485904 |
Coronary artery dissection | 13.10 | 9.60 | 12 | 118953 | 715 | 50485444 |
Feeling abnormal | 13.08 | 9.60 | 387 | 118578 | 125105 | 50361054 |
Breast adenoma | 13.06 | 9.60 | 5 | 118960 | 54 | 50486105 |
Osteoarthritis | 13.03 | 9.60 | 101 | 118864 | 68505 | 50417654 |
Mast cell activation syndrome | 12.97 | 9.60 | 9 | 118956 | 358 | 50485801 |
Impaired work ability | 12.96 | 9.60 | 8 | 118957 | 13632 | 50472527 |
Ovarian cancer recurrent | 12.94 | 9.60 | 13 | 118952 | 869 | 50485290 |
Haemoglobin decreased | 12.91 | 9.60 | 391 | 118574 | 126825 | 50359334 |
Feeling hot | 12.89 | 9.60 | 145 | 118820 | 39057 | 50447102 |
Granulocytopenia | 12.88 | 9.60 | 34 | 118931 | 5197 | 50480962 |
Brain natriuretic peptide increased | 12.79 | 9.60 | 31 | 118934 | 4496 | 50481663 |
Back pain | 12.75 | 9.60 | 636 | 118329 | 219394 | 50266765 |
Putamen haemorrhage | 12.74 | 9.60 | 7 | 118958 | 182 | 50485977 |
Muscle spasticity | 12.66 | 9.60 | 13 | 118952 | 17171 | 50468988 |
Peripheral swelling | 12.64 | 9.60 | 378 | 118587 | 205558 | 50280601 |
Drug tolerance decreased | 12.62 | 9.60 | 3 | 118962 | 9157 | 50477002 |
Pulmonary hypertension | 12.57 | 9.60 | 127 | 118838 | 33290 | 50452869 |
Extrapyramidal disorder | 12.50 | 9.60 | 6 | 118959 | 11764 | 50474395 |
Intentional self-injury | 12.45 | 9.60 | 22 | 118943 | 23090 | 50463069 |
Hyperlipidaemia | 12.43 | 9.60 | 77 | 118888 | 17413 | 50468746 |
Swollen tongue | 12.35 | 9.60 | 112 | 118853 | 28518 | 50457641 |
Emotional distress | 12.30 | 9.60 | 112 | 118853 | 28551 | 50457608 |
Laboratory test abnormal | 12.25 | 9.60 | 95 | 118870 | 23113 | 50463046 |
Ovarian cancer | 12.20 | 9.60 | 33 | 118932 | 5116 | 50481043 |
Lactic acidosis | 12.18 | 9.60 | 39 | 118926 | 33316 | 50452843 |
Allergy test positive | 12.17 | 9.60 | 9 | 118956 | 396 | 50485763 |
Cholestasis | 12.10 | 9.60 | 26 | 118939 | 25375 | 50460784 |
Blood albumin decreased | 11.86 | 9.60 | 62 | 118903 | 13174 | 50472985 |
Blood creatine phosphokinase MB increased | 11.81 | 9.60 | 14 | 118951 | 1128 | 50485031 |
Stress cardiomyopathy | 11.72 | 9.60 | 43 | 118922 | 7844 | 50478315 |
Dermatitis acneiform | 11.69 | 9.60 | 28 | 118937 | 4029 | 50482130 |
Inflammation | 11.66 | 9.60 | 82 | 118883 | 56830 | 50429329 |
Xanthogranuloma | 11.57 | 9.60 | 3 | 118962 | 7 | 50486152 |
Cough | 11.53 | 9.60 | 685 | 118280 | 240579 | 50245580 |
Neurological examination abnormal | 11.44 | 9.60 | 7 | 118958 | 224 | 50485935 |
Renal failure | 11.43 | 9.60 | 330 | 118635 | 106303 | 50379856 |
Lymphocyte count decreased | 11.39 | 9.60 | 103 | 118862 | 26204 | 50459955 |
Blood pressure systolic increased | 11.24 | 9.60 | 44 | 118921 | 35405 | 50450754 |
Respiratory failure | 11.14 | 9.60 | 287 | 118678 | 90894 | 50395265 |
Pleural effusion | 11.03 | 9.60 | 260 | 118705 | 81194 | 50404965 |
Pityriasis lichenoides et varioliformis acuta | 11.00 | 9.60 | 4 | 118961 | 37 | 50486122 |
Palpitations | 10.84 | 9.60 | 295 | 118670 | 94211 | 50391948 |
Seasonal allergy | 10.68 | 9.60 | 65 | 118900 | 14611 | 50471548 |
Allergic transfusion reaction | 10.64 | 9.60 | 4 | 118961 | 41 | 50486118 |
Tinea pedis | 10.63 | 9.60 | 14 | 118951 | 1255 | 50484904 |
Shock | 10.61 | 9.60 | 84 | 118881 | 20566 | 50465593 |
Light chain analysis increased | 10.60 | 9.60 | 13 | 118952 | 1085 | 50485074 |
Stoma site cellulitis | 10.57 | 9.60 | 3 | 118962 | 11 | 50486148 |
Vascular resistance systemic decreased | 10.57 | 9.60 | 5 | 118960 | 94 | 50486065 |
Gastrointestinal haemorrhage | 10.54 | 9.60 | 236 | 118729 | 73085 | 50413074 |
Pyelonephritis acute | 10.52 | 9.60 | 27 | 118938 | 4056 | 50482103 |
Restless arm syndrome | 10.47 | 9.60 | 4 | 118961 | 43 | 50486116 |
Anxiety | 10.41 | 9.60 | 514 | 118451 | 177092 | 50309067 |
Colitis ischaemic | 10.35 | 9.60 | 47 | 118918 | 9436 | 50476723 |
Myocarditis infectious | 10.18 | 9.60 | 3 | 118962 | 13 | 50486146 |
Intraductal papillary breast neoplasm | 10.18 | 9.60 | 3 | 118962 | 13 | 50486146 |
Pneumonia bacterial | 10.15 | 9.60 | 39 | 118926 | 7270 | 50478889 |
Haemolytic anaemia | 10.10 | 9.60 | 46 | 118919 | 9246 | 50476913 |
Haematotoxicity | 10.09 | 9.60 | 3 | 118962 | 7892 | 50478267 |
Joint stiffness | 10.01 | 9.60 | 37 | 118928 | 30271 | 50455888 |
Reticulocyte percentage increased | 10.00 | 9.60 | 3 | 118962 | 14 | 50486145 |
Status asthmaticus | 9.94 | 9.60 | 11 | 118954 | 822 | 50485337 |
Neuroleptic malignant syndrome | 9.94 | 9.60 | 7 | 118958 | 11123 | 50475036 |
Anaplastic astrocytoma | 9.86 | 9.60 | 4 | 118961 | 51 | 50486108 |
Therapeutic hypothermia | 9.83 | 9.60 | 3 | 118962 | 15 | 50486144 |
Mean arterial pressure increased | 9.83 | 9.60 | 3 | 118962 | 15 | 50486144 |
Aplastic anaemia | 9.81 | 9.60 | 40 | 118925 | 7663 | 50478496 |
Hypersensitivity | 9.75 | 9.60 | 410 | 118555 | 214751 | 50271408 |
Tinnitus | 9.68 | 9.60 | 105 | 118860 | 28027 | 50458132 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective | 176.81 | 9.78 | 483 | 82445 | 362687 | 29128912 |
Hepatic function abnormal | 154.96 | 9.78 | 341 | 82587 | 38918 | 29452681 |
Drug abuse | 144.42 | 9.78 | 25 | 82903 | 79858 | 29411741 |
Toxicity to various agents | 105.95 | 9.78 | 204 | 82724 | 173457 | 29318142 |
Platelet count decreased | 99.65 | 9.78 | 566 | 82362 | 104106 | 29387493 |
Off label use | 98.29 | 9.78 | 472 | 82456 | 300328 | 29191271 |
Alanine aminotransferase increased | 97.64 | 9.78 | 426 | 82502 | 70518 | 29421081 |
Aspartate aminotransferase increased | 94.22 | 9.78 | 374 | 82554 | 59351 | 29432248 |
Liver disorder | 92.92 | 9.78 | 226 | 82702 | 27523 | 29464076 |
Completed suicide | 87.04 | 9.78 | 75 | 82853 | 90171 | 29401428 |
Disseminated intravascular coagulation | 77.04 | 9.78 | 172 | 82756 | 19808 | 29471791 |
White blood cell count decreased | 69.17 | 9.78 | 435 | 82493 | 82927 | 29408672 |
General physical health deterioration | 62.48 | 9.78 | 121 | 82807 | 102736 | 29388863 |
Drug interaction | 57.93 | 9.78 | 321 | 82607 | 197064 | 29294535 |
Neutrophil count decreased | 53.46 | 9.78 | 253 | 82675 | 43314 | 29448285 |
Blood lactate dehydrogenase increased | 44.80 | 9.78 | 137 | 82791 | 19072 | 29472527 |
Chronic kidney disease | 44.33 | 9.78 | 211 | 82717 | 36205 | 29455394 |
Drug resistance | 42.96 | 9.78 | 5 | 82923 | 21535 | 29470064 |
Interstitial lung disease | 40.50 | 9.78 | 289 | 82639 | 57429 | 29434170 |
Treatment failure | 40.31 | 9.78 | 27 | 82901 | 36912 | 29454687 |
Upper respiratory tract inflammation | 38.99 | 9.78 | 34 | 82894 | 1586 | 29490013 |
Product use in unapproved indication | 33.96 | 9.78 | 127 | 82801 | 86748 | 29404851 |
Cerebral infarction | 33.76 | 9.78 | 148 | 82780 | 24527 | 29467072 |
Blood alkaline phosphatase increased | 33.42 | 9.78 | 163 | 82765 | 28243 | 29463356 |
Lymphocyte stimulation test positive | 33.10 | 9.78 | 22 | 82906 | 679 | 29490920 |
Overdose | 32.98 | 9.78 | 114 | 82814 | 79705 | 29411894 |
Drug intolerance | 30.15 | 9.78 | 56 | 82872 | 48323 | 29443276 |
Pyrexia | 29.75 | 9.78 | 1034 | 81894 | 286588 | 29205011 |
Infusion related reaction | 29.20 | 9.78 | 217 | 82711 | 43669 | 29447930 |
Contraindicated product administered | 28.38 | 9.78 | 8 | 82920 | 18258 | 29473341 |
Rheumatoid arthritis | 28.29 | 9.78 | 29 | 82899 | 32123 | 29459476 |
Pneumonitis | 27.51 | 9.78 | 153 | 82775 | 27891 | 29463708 |
Pneumonia | 27.14 | 9.78 | 1126 | 81802 | 319046 | 29172553 |
Foetal exposure during pregnancy | 27.11 | 9.78 | 33 | 82895 | 33834 | 29457765 |
Therapeutic product effect incomplete | 26.77 | 9.78 | 43 | 82885 | 39262 | 29452337 |
Acute respiratory failure | 25.87 | 9.78 | 144 | 82784 | 26258 | 29465341 |
Decreased appetite | 25.33 | 9.78 | 559 | 82369 | 144783 | 29346816 |
Aplastic anaemia | 24.95 | 9.78 | 61 | 82867 | 7449 | 29484150 |
Intentional product misuse | 23.53 | 9.78 | 38 | 82890 | 34623 | 29456976 |
Blood bilirubin increased | 23.35 | 9.78 | 169 | 82759 | 33724 | 29457875 |
Intentional product use issue | 22.45 | 9.78 | 54 | 82874 | 42444 | 29449155 |
Blood urea increased | 22.23 | 9.78 | 145 | 82783 | 27967 | 29463632 |
Blood creatine phosphokinase MB increased | 22.18 | 9.78 | 26 | 82902 | 1731 | 29489868 |
Pneumonia bacterial | 22.12 | 9.78 | 67 | 82861 | 9276 | 29482323 |
Burkholderia test positive | 22.12 | 9.78 | 20 | 82908 | 979 | 29490620 |
Erythema multiforme | 21.83 | 9.78 | 59 | 82869 | 7658 | 29483941 |
Rash | 21.51 | 9.78 | 690 | 82238 | 189129 | 29302470 |
Hypoxia | 21.39 | 9.78 | 215 | 82713 | 47164 | 29444435 |
Haematocrit decreased | 21.33 | 9.78 | 147 | 82781 | 28875 | 29462724 |
Febrile neutropenia | 21.25 | 9.78 | 437 | 82491 | 111803 | 29379796 |
Infective pulmonary exacerbation of cystic fibrosis | 20.02 | 9.78 | 50 | 82878 | 6186 | 29485413 |
Enterocolitis | 19.90 | 9.78 | 52 | 82876 | 6614 | 29484985 |
Blood albumin decreased | 19.85 | 9.78 | 75 | 82853 | 11620 | 29479979 |
End stage renal disease | 19.13 | 9.78 | 56 | 82872 | 7608 | 29483991 |
Joint swelling | 19.09 | 9.78 | 73 | 82855 | 49557 | 29442042 |
Plasma cell myeloma | 18.52 | 9.78 | 172 | 82756 | 36943 | 29454656 |
Constipation | 17.38 | 9.78 | 431 | 82497 | 113729 | 29377870 |
Intentional overdose | 17.31 | 9.78 | 53 | 82875 | 38475 | 29453124 |
Cholangitis acute | 17.30 | 9.78 | 15 | 82913 | 694 | 29490905 |
Pneumonia aspiration | 17.21 | 9.78 | 168 | 82760 | 36569 | 29455030 |
Lactic acidosis | 17.14 | 9.78 | 37 | 82891 | 30210 | 29461389 |
Human ehrlichiosis | 16.42 | 9.78 | 9 | 82919 | 194 | 29491405 |
Ventricular tachycardia | 16.39 | 9.78 | 114 | 82814 | 22460 | 29469139 |
Wound secretion | 16.38 | 9.78 | 26 | 82902 | 2312 | 29489287 |
Urticaria | 16.25 | 9.78 | 229 | 82699 | 54431 | 29437168 |
Blood pressure ambulatory increased | 16.12 | 9.78 | 6 | 82922 | 49 | 29491550 |
Cytokine release syndrome | 15.94 | 9.78 | 76 | 82852 | 13043 | 29478556 |
PO2 increased | 15.38 | 9.78 | 13 | 82915 | 581 | 29491018 |
Gastrointestinal mucosal necrosis | 15.13 | 9.78 | 8 | 82920 | 160 | 29491439 |
Eczema asteatotic | 14.95 | 9.78 | 8 | 82920 | 164 | 29491435 |
Anaphylactic reaction | 14.89 | 9.78 | 130 | 82798 | 27443 | 29464156 |
Cardiac autonomic neuropathy | 14.89 | 9.78 | 6 | 82922 | 62 | 29491537 |
Renal impairment | 14.84 | 9.78 | 315 | 82613 | 81018 | 29410581 |
Catheter site haemorrhage | 14.66 | 9.78 | 23 | 82905 | 2025 | 29489574 |
Glossectomy | 14.64 | 9.78 | 3 | 82925 | 0 | 29491599 |
Lower respiratory tract infection | 14.53 | 9.78 | 33 | 82895 | 26469 | 29465130 |
CADASIL | 14.47 | 9.78 | 6 | 82922 | 67 | 29491532 |
Sepsis | 14.44 | 9.78 | 512 | 82416 | 142170 | 29349429 |
Hiccups | 14.39 | 9.78 | 56 | 82872 | 8797 | 29482802 |
Mast cell activation syndrome | 14.37 | 9.78 | 8 | 82920 | 178 | 29491421 |
Arthropathy | 14.28 | 9.78 | 24 | 82904 | 21530 | 29470069 |
Magnetic resonance imaging spinal abnormal | 14.16 | 9.78 | 6 | 82922 | 71 | 29491528 |
Torsade de pointes | 14.14 | 9.78 | 46 | 82882 | 6615 | 29484984 |
Psychotic disorder | 14.11 | 9.78 | 22 | 82906 | 20332 | 29471267 |
Musculoskeletal stiffness | 13.83 | 9.78 | 56 | 82872 | 37402 | 29454197 |
Visual evoked potentials abnormal | 13.80 | 9.78 | 6 | 82922 | 76 | 29491523 |
Hepatocellular injury | 13.76 | 9.78 | 24 | 82904 | 21219 | 29470380 |
Blood pressure decreased | 13.71 | 9.78 | 191 | 82737 | 45286 | 29446313 |
Respiratory failure | 13.69 | 9.78 | 363 | 82565 | 96768 | 29394831 |
Stomatitis | 13.34 | 9.78 | 161 | 82767 | 36952 | 29454647 |
Drug dependence | 13.32 | 9.78 | 24 | 82904 | 20957 | 29470642 |
Protein total decreased | 13.32 | 9.78 | 35 | 82893 | 4467 | 29487132 |
Product use issue | 13.28 | 9.78 | 87 | 82841 | 51357 | 29440242 |
Burkholderia infection | 13.20 | 9.78 | 6 | 82922 | 85 | 29491514 |
Polyneuropathy | 13.10 | 9.78 | 9 | 82919 | 12143 | 29479456 |
Pneumonia staphylococcal | 13.08 | 9.78 | 26 | 82902 | 2759 | 29488840 |
Convulsive threshold lowered | 13.01 | 9.78 | 11 | 82917 | 492 | 29491107 |
Accidental exposure to product | 12.93 | 9.78 | 7 | 82921 | 10746 | 29480853 |
Supine hypertension | 12.85 | 9.78 | 9 | 82919 | 303 | 29491296 |
Convulsions local | 12.75 | 9.78 | 4 | 82924 | 18 | 29491581 |
Rash maculo-papular | 12.72 | 9.78 | 31 | 82897 | 24258 | 29467341 |
Inappropriate schedule of product administration | 12.63 | 9.78 | 73 | 82855 | 44399 | 29447200 |
Sputum retention | 12.49 | 9.78 | 10 | 82918 | 414 | 29491185 |
Central nervous system inflammation | 12.27 | 9.78 | 6 | 82922 | 101 | 29491498 |
Cardiogenic shock | 12.14 | 9.78 | 22 | 82906 | 19168 | 29472431 |
Anal erosion | 12.09 | 9.78 | 4 | 82924 | 22 | 29491577 |
Cerebral microangiopathy | 12.02 | 9.78 | 7 | 82921 | 170 | 29491429 |
Aggression | 11.98 | 9.78 | 55 | 82873 | 35486 | 29456113 |
White blood cell count increased | 11.89 | 9.78 | 159 | 82769 | 37357 | 29454242 |
Amino acid level decreased | 11.74 | 9.78 | 5 | 82923 | 60 | 29491539 |
Amino acid level increased | 11.63 | 9.78 | 9 | 82919 | 354 | 29491245 |
Hyperuricaemia | 11.54 | 9.78 | 44 | 82884 | 6845 | 29484754 |
Progressive multifocal leukoencephalopathy | 11.52 | 9.78 | 5 | 82923 | 8714 | 29482885 |
Post procedural haematoma | 11.47 | 9.78 | 17 | 82911 | 1424 | 29490175 |
Jaundice hepatocellular | 11.45 | 9.78 | 5 | 82923 | 64 | 29491535 |
Hypoalbuminaemia | 11.31 | 9.78 | 58 | 82870 | 10247 | 29481352 |
Metabolic encephalopathy | 11.25 | 9.78 | 29 | 82899 | 3658 | 29487941 |
Stevens-Johnson syndrome | 11.21 | 9.78 | 82 | 82846 | 16415 | 29475184 |
Gastrointestinal tract mucosal pigmentation | 11.21 | 9.78 | 9 | 82919 | 374 | 29491225 |
Hypertensive crisis | 11.19 | 9.78 | 4 | 82924 | 7844 | 29483755 |
Granulocyte count decreased | 10.97 | 9.78 | 11 | 82917 | 613 | 29490986 |
Conduction disorder | 10.93 | 9.78 | 19 | 82909 | 1821 | 29489778 |
Saccadic eye movement | 10.92 | 9.78 | 6 | 82922 | 130 | 29491469 |
Viral rash | 10.87 | 9.78 | 5 | 82923 | 73 | 29491526 |
Hepatitis fulminant | 10.81 | 9.78 | 28 | 82900 | 3543 | 29488056 |
Suicide attempt | 10.79 | 9.78 | 54 | 82874 | 34056 | 29457543 |
Blood pressure fluctuation | 10.72 | 9.78 | 25 | 82903 | 19869 | 29471730 |
Acute kidney injury | 10.66 | 9.78 | 622 | 82306 | 264645 | 29226954 |
Pulmonary fibrosis | 10.65 | 9.78 | 17 | 82911 | 15565 | 29476034 |
Ventricular flutter | 10.57 | 9.78 | 5 | 82923 | 78 | 29491521 |
Coma | 10.55 | 9.78 | 66 | 82862 | 39384 | 29452215 |
Gamma-glutamyltransferase increased | 10.51 | 9.78 | 118 | 82810 | 26619 | 29464980 |
Substance abuse | 10.49 | 9.78 | 3 | 82925 | 6784 | 29484815 |
Arthralgia | 10.39 | 9.78 | 305 | 82623 | 139312 | 29352287 |
Respiratory symptom | 10.32 | 9.78 | 13 | 82915 | 933 | 29490666 |
Sputum culture positive | 10.29 | 9.78 | 18 | 82910 | 1734 | 29489865 |
Haematotoxicity | 10.28 | 9.78 | 3 | 82925 | 6696 | 29484903 |
Ejaculation delayed | 10.15 | 9.78 | 7 | 82921 | 230 | 29491369 |
Blood pH decreased | 10.13 | 9.78 | 20 | 82908 | 2113 | 29489486 |
Flushing | 10.09 | 9.78 | 125 | 82803 | 28867 | 29462732 |
Loss of personal independence in daily activities | 10.05 | 9.78 | 37 | 82891 | 25403 | 29466196 |
Tunnel vision | 10.03 | 9.78 | 9 | 82919 | 436 | 29491163 |
Retroperitoneal abscess | 9.91 | 9.78 | 6 | 82922 | 157 | 29491442 |
Injection site pain | 9.90 | 9.78 | 52 | 82876 | 32394 | 29459205 |
Granulocytopenia | 9.81 | 9.78 | 38 | 82890 | 5956 | 29485643 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective | 403.80 | 9.32 | 950 | 160696 | 839297 | 63497789 |
Hepatic function abnormal | 249.49 | 9.32 | 519 | 161127 | 63794 | 64273292 |
Drug abuse | 207.40 | 9.32 | 40 | 161606 | 132334 | 64204752 |
Drug intolerance | 202.99 | 9.32 | 109 | 161537 | 187883 | 64149203 |
Platelet count decreased | 189.00 | 9.32 | 877 | 160769 | 166834 | 64170252 |
Synovitis | 188.63 | 9.32 | 16 | 161630 | 99074 | 64238012 |
Contraindicated product administered | 188.32 | 9.32 | 24 | 161622 | 107805 | 64229281 |
Joint swelling | 173.80 | 9.32 | 170 | 161476 | 215212 | 64121874 |
Off label use | 169.08 | 9.32 | 915 | 160731 | 631891 | 63705195 |
Toxicity to various agents | 165.79 | 9.32 | 421 | 161225 | 363092 | 63973994 |
Rheumatoid arthritis | 150.34 | 9.32 | 115 | 161531 | 164179 | 64172907 |
Aspartate aminotransferase increased | 148.85 | 9.32 | 645 | 161001 | 119143 | 64217943 |
Arthropathy | 146.15 | 9.32 | 60 | 161586 | 120907 | 64216179 |
Alanine aminotransferase increased | 139.26 | 9.32 | 703 | 160943 | 138328 | 64198758 |
Pemphigus | 137.42 | 9.32 | 3 | 161643 | 60698 | 64276388 |
White blood cell count decreased | 135.55 | 9.32 | 765 | 160881 | 157072 | 64180014 |
Liver disorder | 133.42 | 9.32 | 363 | 161283 | 52988 | 64284098 |
Treatment failure | 125.65 | 9.32 | 68 | 161578 | 116748 | 64220338 |
Disseminated intravascular coagulation | 121.84 | 9.32 | 258 | 161388 | 32090 | 64304996 |
Hand deformity | 119.83 | 9.32 | 10 | 161636 | 62761 | 64274325 |
Therapeutic product effect decreased | 118.55 | 9.32 | 71 | 161575 | 115280 | 64221806 |
Completed suicide | 111.66 | 9.32 | 248 | 161398 | 224166 | 64112920 |
Pneumonia aspiration | 108.25 | 9.32 | 361 | 161285 | 58910 | 64278176 |
Cytokine release syndrome | 107.72 | 9.32 | 190 | 161456 | 20639 | 64316447 |
General physical health deterioration | 107.47 | 9.32 | 219 | 161427 | 204206 | 64132880 |
Lower respiratory tract infection | 93.40 | 9.32 | 61 | 161585 | 94553 | 64242533 |
Gastrooesophageal reflux disease | 87.16 | 9.32 | 426 | 161220 | 82717 | 64254369 |
Neutrophil count decreased | 85.60 | 9.32 | 402 | 161244 | 76794 | 64260292 |
Blood lactate dehydrogenase increased | 84.63 | 9.32 | 227 | 161419 | 32851 | 64304235 |
Arthralgia | 82.65 | 9.32 | 710 | 160936 | 441550 | 63895536 |
Type I hypersensitivity | 78.81 | 9.32 | 68 | 161578 | 3506 | 64333580 |
Glossodynia | 76.66 | 9.32 | 33 | 161613 | 64663 | 64272423 |
Interstitial lung disease | 74.36 | 9.32 | 459 | 161187 | 97273 | 64239813 |
Systemic lupus erythematosus | 72.66 | 9.32 | 53 | 161593 | 77559 | 64259527 |
Chronic kidney disease | 68.19 | 9.32 | 307 | 161339 | 57612 | 64279474 |
Pericarditis | 67.78 | 9.32 | 36 | 161610 | 62480 | 64274606 |
Upper respiratory tract inflammation | 67.72 | 9.32 | 64 | 161582 | 3718 | 64333368 |
Cerebral infarction | 65.41 | 9.32 | 239 | 161407 | 40805 | 64296281 |
Therapeutic product effect incomplete | 63.18 | 9.32 | 101 | 161545 | 103381 | 64233705 |
Duodenal ulcer perforation | 62.17 | 9.32 | 7 | 161639 | 34618 | 64302468 |
Flushing | 61.48 | 9.32 | 372 | 161274 | 78276 | 64258810 |
Musculoskeletal stiffness | 61.36 | 9.32 | 136 | 161510 | 123070 | 64214016 |
Helicobacter infection | 61.32 | 9.32 | 11 | 161635 | 38351 | 64298735 |
Sopor | 58.66 | 9.32 | 4 | 161642 | 29657 | 64307429 |
Lymphocyte stimulation test positive | 56.53 | 9.32 | 35 | 161611 | 1071 | 64336015 |
Wound | 56.43 | 9.32 | 65 | 161581 | 76412 | 64260674 |
Drug resistance | 56.25 | 9.32 | 10 | 161636 | 35092 | 64301994 |
Product use issue | 54.45 | 9.32 | 196 | 161450 | 151519 | 64185567 |
Sleep disorder due to general medical condition, insomnia type | 53.58 | 9.32 | 3 | 161643 | 26267 | 64310819 |
Overdose | 52.84 | 9.32 | 213 | 161433 | 159353 | 64177733 |
Blood alkaline phosphatase increased | 52.42 | 9.32 | 279 | 161367 | 56000 | 64281086 |
Acute respiratory failure | 51.71 | 9.32 | 255 | 161391 | 49679 | 64287407 |
Enterocolitis | 51.34 | 9.32 | 101 | 161545 | 11917 | 64325169 |
Mobility decreased | 51.25 | 9.32 | 85 | 161561 | 85755 | 64251331 |
Drug hypersensitivity | 49.29 | 9.32 | 371 | 161275 | 237444 | 64099642 |
Decreased appetite | 48.68 | 9.32 | 982 | 160664 | 280307 | 64056779 |
Discomfort | 48.37 | 9.32 | 80 | 161566 | 80798 | 64256288 |
Muscle injury | 48.35 | 9.32 | 5 | 161641 | 26432 | 64310654 |
Pneumonia | 47.97 | 9.32 | 1783 | 159863 | 557793 | 63779293 |
Red blood cell sedimentation rate increased | 47.72 | 9.32 | 10 | 161636 | 31225 | 64305861 |
Pyrexia | 47.64 | 9.32 | 1779 | 159867 | 556865 | 63780221 |
Cholecystitis chronic | 47.10 | 9.32 | 84 | 161562 | 9203 | 64327883 |
Maternal exposure during pregnancy | 45.98 | 9.32 | 108 | 161538 | 95776 | 64241310 |
Drug interaction | 45.98 | 9.32 | 635 | 161011 | 361448 | 63975638 |
Febrile neutropenia | 44.94 | 9.32 | 690 | 160956 | 186967 | 64150119 |
Infective pulmonary exacerbation of cystic fibrosis | 44.31 | 9.32 | 94 | 161552 | 11702 | 64325384 |
Blood bilirubin increased | 44.19 | 9.32 | 271 | 161375 | 57282 | 64279804 |
Hypoxia | 43.89 | 9.32 | 374 | 161272 | 87775 | 64249311 |
Folliculitis | 43.22 | 9.32 | 11 | 161635 | 30066 | 64307020 |
Hepatocellular injury | 42.19 | 9.32 | 31 | 161615 | 45204 | 64291882 |
Alopecia | 42.14 | 9.32 | 243 | 161403 | 165447 | 64171639 |
Butterfly rash | 40.12 | 9.32 | 29 | 161617 | 1153 | 64335933 |
Anaphylactic reaction | 39.43 | 9.32 | 301 | 161345 | 68363 | 64268723 |
Urticaria | 39.32 | 9.32 | 552 | 161094 | 146765 | 64190321 |
Torsade de pointes | 38.36 | 9.32 | 113 | 161533 | 17250 | 64319836 |
Blood pressure fluctuation | 37.28 | 9.32 | 45 | 161601 | 51826 | 64285260 |
Dehydration | 36.57 | 9.32 | 754 | 160892 | 216009 | 64121077 |
Erythema multiforme | 36.44 | 9.32 | 104 | 161542 | 15597 | 64321489 |
Plasma cell myeloma | 36.04 | 9.32 | 218 | 161428 | 45857 | 64291229 |
Psoriatic arthropathy | 35.04 | 9.32 | 34 | 161612 | 43247 | 64293839 |
Sepsis | 34.93 | 9.32 | 789 | 160857 | 229552 | 64107534 |
Aplastic anaemia | 34.07 | 9.32 | 94 | 161552 | 13826 | 64323260 |
Weight increased | 33.98 | 9.32 | 356 | 161290 | 212992 | 64124094 |
Blood creatine phosphokinase MB increased | 33.53 | 9.32 | 37 | 161609 | 2584 | 64334502 |
Hepatic enzyme increased | 33.34 | 9.32 | 190 | 161456 | 129753 | 64207333 |
Intentional product use issue | 33.02 | 9.32 | 125 | 161521 | 95239 | 64241847 |
Protein total decreased | 31.87 | 9.32 | 65 | 161581 | 7871 | 64329215 |
Irritable bowel syndrome | 31.86 | 9.32 | 28 | 161618 | 37341 | 64299745 |
Chest discomfort | 31.76 | 9.32 | 437 | 161209 | 115669 | 64221417 |
Pneumonia bacterial | 31.47 | 9.32 | 96 | 161550 | 14939 | 64322147 |
Haematocrit decreased | 31.05 | 9.32 | 239 | 161407 | 54416 | 64282670 |
Drug eruption | 30.86 | 9.32 | 175 | 161471 | 35961 | 64301125 |
Blood urea increased | 30.86 | 9.32 | 203 | 161443 | 43950 | 64293136 |
Pneumonitis | 30.74 | 9.32 | 224 | 161422 | 50141 | 64286945 |
Pain | 30.22 | 9.32 | 1109 | 160537 | 552402 | 63784684 |
Knee arthroplasty | 30.08 | 9.32 | 15 | 161631 | 26984 | 64310102 |
Blood albumin decreased | 29.69 | 9.32 | 118 | 161528 | 20955 | 64316131 |
Impaired healing | 29.08 | 9.32 | 68 | 161578 | 60405 | 64276681 |
Ill-defined disorder | 28.80 | 9.32 | 41 | 161605 | 44011 | 64293075 |
Swelling | 28.60 | 9.32 | 260 | 161386 | 159958 | 64177128 |
Mental status changes | 28.10 | 9.32 | 255 | 161391 | 60907 | 64276179 |
Ventricular tachycardia | 28.00 | 9.32 | 164 | 161482 | 34101 | 64302985 |
Injection site pain | 27.99 | 9.32 | 164 | 161482 | 111244 | 64225842 |
White blood cell count increased | 27.72 | 9.32 | 270 | 161376 | 65744 | 64271342 |
Lactic acidosis | 27.23 | 9.32 | 72 | 161574 | 61338 | 64275748 |
Renal impairment | 26.26 | 9.32 | 480 | 161166 | 134537 | 64202549 |
Angioedema | 26.03 | 9.32 | 253 | 161393 | 61568 | 64275518 |
Blood pressure systolic increased | 25.93 | 9.32 | 53 | 161593 | 49400 | 64287686 |
End stage renal disease | 25.90 | 9.32 | 71 | 161575 | 10404 | 64326682 |
Fibromyalgia | 25.68 | 9.32 | 31 | 161615 | 35700 | 64301386 |
Loss of personal independence in daily activities | 25.06 | 9.32 | 95 | 161551 | 72359 | 64264727 |
Chills | 24.97 | 9.32 | 483 | 161163 | 136781 | 64200305 |
Arthritis | 24.61 | 9.32 | 117 | 161529 | 83697 | 64253389 |
Gastrointestinal disorder | 24.19 | 9.32 | 129 | 161517 | 89580 | 64247506 |
Granulocytopenia | 24.08 | 9.32 | 69 | 161577 | 10371 | 64326715 |
Periorbital oedema | 23.27 | 9.32 | 55 | 161591 | 7359 | 64329727 |
Haemorrhage subcutaneous | 22.83 | 9.32 | 40 | 161606 | 4321 | 64332765 |
Pain in extremity | 22.70 | 9.32 | 582 | 161064 | 302503 | 64034583 |
Product use in unapproved indication | 22.64 | 9.32 | 309 | 161337 | 176309 | 64160777 |
Intentional product misuse | 22.37 | 9.32 | 99 | 161547 | 72196 | 64264890 |
Constipation | 22.35 | 9.32 | 742 | 160904 | 228595 | 64108491 |
Polyneuropathy | 22.24 | 9.32 | 11 | 161635 | 19883 | 64317203 |
Hyperuricaemia | 22.21 | 9.32 | 66 | 161580 | 10125 | 64326961 |
Burkholderia test positive | 21.49 | 9.32 | 15 | 161631 | 564 | 64336522 |
Peripheral swelling | 21.37 | 9.32 | 382 | 161264 | 208771 | 64128315 |
Respiratory failure | 21.34 | 9.32 | 542 | 161104 | 160641 | 64176445 |
Asteatosis | 21.31 | 9.32 | 8 | 161638 | 76 | 64337010 |
Lip swelling | 21.27 | 9.32 | 145 | 161501 | 31762 | 64305324 |
Hepatotoxicity | 20.81 | 9.32 | 43 | 161603 | 39919 | 64297167 |
Blood pressure diastolic abnormal | 19.97 | 9.32 | 3 | 161643 | 11914 | 64325172 |
Gallbladder disorder | 19.83 | 9.32 | 90 | 161556 | 16940 | 64320146 |
Tenosynovitis | 19.79 | 9.32 | 3 | 161643 | 11830 | 64325256 |
Haemoglobin decreased | 19.75 | 9.32 | 634 | 161012 | 194429 | 64142657 |
Swelling face | 19.27 | 9.32 | 230 | 161416 | 58936 | 64278150 |
Exposure during pregnancy | 19.16 | 9.32 | 115 | 161531 | 77560 | 64259526 |
Medication error | 18.96 | 9.32 | 63 | 161583 | 49903 | 64287183 |
Nasopharyngitis | 18.82 | 9.32 | 362 | 161284 | 195711 | 64141375 |
Cholecystitis acute | 18.82 | 9.32 | 67 | 161579 | 11293 | 64325793 |
Intentional overdose | 18.76 | 9.32 | 140 | 161506 | 89804 | 64247282 |
Urinary tract infection | 18.57 | 9.32 | 733 | 160913 | 230863 | 64106223 |
Biliary dyskinesia | 18.31 | 9.32 | 26 | 161620 | 2346 | 64334740 |
Palmar erythema | 18.27 | 9.32 | 22 | 161624 | 1688 | 64335398 |
Cholestasis | 18.13 | 9.32 | 55 | 161591 | 44817 | 64292269 |
Small intestinal obstruction | 17.46 | 9.32 | 110 | 161536 | 23463 | 64313623 |
Blood magnesium decreased | 17.34 | 9.32 | 75 | 161571 | 13830 | 64323256 |
Hospice care | 17.20 | 9.32 | 50 | 161596 | 7575 | 64329511 |
Abdominal discomfort | 17.07 | 9.32 | 338 | 161308 | 181984 | 64155102 |
Hip arthroplasty | 17.02 | 9.32 | 17 | 161629 | 21334 | 64315752 |
Basophil count decreased | 17.00 | 9.32 | 9 | 161637 | 203 | 64336883 |
Tubulointerstitial nephritis | 16.91 | 9.32 | 134 | 161512 | 30775 | 64306311 |
Stevens-Johnson syndrome | 16.87 | 9.32 | 145 | 161501 | 34104 | 64302982 |
Non-cardiac chest pain | 16.85 | 9.32 | 54 | 161592 | 8626 | 64328460 |
Blood pressure ambulatory increased | 16.67 | 9.32 | 6 | 161640 | 50 | 64337036 |
Disease progression | 16.63 | 9.32 | 469 | 161177 | 141211 | 64195875 |
Pleural effusion | 16.58 | 9.32 | 425 | 161221 | 126134 | 64210952 |
Deep vein thrombosis | 16.46 | 9.32 | 362 | 161284 | 104820 | 64232266 |
Therapeutic response decreased | 16.43 | 9.32 | 71 | 161575 | 52117 | 64284969 |
Balance disorder | 16.39 | 9.32 | 133 | 161513 | 83793 | 64253293 |
Blood potassium decreased | 16.36 | 9.32 | 164 | 161482 | 40235 | 64296851 |
Inappropriate schedule of product administration | 16.35 | 9.32 | 150 | 161496 | 92136 | 64244950 |
Ventricular flutter | 16.29 | 9.32 | 7 | 161639 | 97 | 64336989 |
Extrapyramidal disorder | 16.25 | 9.32 | 15 | 161631 | 19537 | 64317549 |
Throat irritation | 15.86 | 9.32 | 138 | 161508 | 32573 | 64304513 |
Injection site bruising | 15.86 | 9.32 | 43 | 161603 | 36330 | 64300756 |
Heart rate decreased | 15.51 | 9.32 | 78 | 161568 | 54989 | 64282097 |
Therapy non-responder | 15.50 | 9.32 | 99 | 161547 | 65800 | 64271286 |
Basal cell carcinoma | 15.37 | 9.32 | 34 | 161612 | 30804 | 64306282 |
Chest pain | 15.37 | 9.32 | 731 | 160915 | 235249 | 64101837 |
Blister | 15.05 | 9.32 | 130 | 161516 | 80837 | 64256249 |
Psychotic disorder | 14.98 | 9.32 | 41 | 161605 | 34537 | 64302549 |
Glossectomy | 14.98 | 9.32 | 3 | 161643 | 0 | 64337086 |
Emotional distress | 14.93 | 9.32 | 147 | 161499 | 35891 | 64301195 |
Musculoskeletal pain | 14.90 | 9.32 | 131 | 161515 | 81163 | 64255923 |
Renal injury | 14.71 | 9.32 | 77 | 161569 | 15352 | 64321734 |
Throat tightness | 14.70 | 9.32 | 104 | 161542 | 23056 | 64314030 |
Hypoalbuminaemia | 14.70 | 9.32 | 85 | 161561 | 17589 | 64319497 |
Cholangitis acute | 14.69 | 9.32 | 17 | 161629 | 1251 | 64335835 |
Neuroleptic malignant syndrome | 14.68 | 9.32 | 25 | 161621 | 24971 | 64312115 |
Autoimmune hepatitis | 14.64 | 9.32 | 57 | 161589 | 10027 | 64327059 |
Gastrointestinal mucosal necrosis | 14.63 | 9.32 | 8 | 161638 | 193 | 64336893 |
Haematotoxicity | 14.61 | 9.32 | 7 | 161639 | 12889 | 64324197 |
Congenital neuropathy | 14.45 | 9.32 | 4 | 161642 | 12 | 64337074 |
Contusion | 14.37 | 9.32 | 200 | 161446 | 113765 | 64223321 |
Gallbladder injury | 14.33 | 9.32 | 16 | 161630 | 1132 | 64335954 |
Drug dependence | 14.06 | 9.32 | 40 | 161606 | 33272 | 64303814 |
Pulmonary fibrosis | 14.04 | 9.32 | 34 | 161612 | 29844 | 64307242 |
Hypertensive crisis | 14.01 | 9.32 | 15 | 161631 | 18233 | 64318853 |
Red blood cell count decreased | 14.00 | 9.32 | 184 | 161462 | 48202 | 64288884 |
Blood creatinine increased | 13.91 | 9.32 | 442 | 161204 | 135340 | 64201746 |
Circulatory collapse | 13.88 | 9.32 | 41 | 161605 | 33691 | 64303395 |
Anaplastic astrocytoma | 13.80 | 9.32 | 7 | 161639 | 144 | 64336942 |
Dermatitis atopic | 13.54 | 9.32 | 30 | 161616 | 3846 | 64333240 |
Brain natriuretic peptide increased | 13.49 | 9.32 | 46 | 161600 | 7587 | 64329499 |
Impaired work ability | 13.47 | 9.32 | 11 | 161635 | 15208 | 64321878 |
Gamma-glutamyltransferase increased | 13.43 | 9.32 | 183 | 161463 | 48327 | 64288759 |
Ventricular fibrillation | 13.36 | 9.32 | 104 | 161542 | 23756 | 64313330 |
Post procedural haematoma | 13.25 | 9.32 | 22 | 161624 | 2276 | 64334810 |
Therapy cessation | 13.21 | 9.32 | 132 | 161514 | 32357 | 64304729 |
Suicide attempt | 13.20 | 9.32 | 114 | 161532 | 70893 | 64266193 |
Fibrin D dimer increased | 13.06 | 9.32 | 42 | 161604 | 6723 | 64330363 |
Cardiac autonomic neuropathy | 13.01 | 9.32 | 5 | 161641 | 51 | 64337035 |
Status asthmaticus | 12.97 | 9.32 | 14 | 161632 | 954 | 64336132 |
Administration site inflammation | 12.90 | 9.32 | 3 | 161643 | 3 | 64337083 |
Acquired haemophilia | 12.87 | 9.32 | 18 | 161628 | 1602 | 64335484 |
Haemodialysis | 12.85 | 9.32 | 80 | 161566 | 16997 | 64320089 |
Osteoporosis | 12.79 | 9.32 | 58 | 161588 | 42022 | 64295064 |
Toxic epidermal necrolysis | 12.77 | 9.32 | 146 | 161500 | 37020 | 64300066 |
Milk allergy | 12.76 | 9.32 | 6 | 161640 | 104 | 64336982 |
Breast adenoma | 12.75 | 9.32 | 5 | 161641 | 54 | 64337032 |
Sedation complication | 12.72 | 9.32 | 5 | 161641 | 10349 | 64326737 |
Anaphylactoid reaction | 12.61 | 9.32 | 33 | 161613 | 4705 | 64332381 |
Condition aggravated | 12.54 | 9.32 | 785 | 160861 | 371641 | 63965445 |
Hypervolaemia | 12.54 | 9.32 | 149 | 161497 | 38136 | 64298950 |
Therapy partial responder | 12.50 | 9.32 | 5 | 161641 | 10243 | 64326843 |
Pathogen resistance | 12.49 | 9.32 | 8 | 161638 | 12535 | 64324551 |
Hereditary angioedema | 12.43 | 9.32 | 29 | 161617 | 3847 | 64333239 |
Sputum culture positive | 12.41 | 9.32 | 25 | 161621 | 3001 | 64334085 |
Accidental exposure to product | 12.39 | 9.32 | 30 | 161616 | 26334 | 64310752 |
Musculoskeletal disorder | 12.38 | 9.32 | 16 | 161630 | 17890 | 64319196 |
Blood pressure decreased | 12.34 | 9.32 | 293 | 161353 | 85906 | 64251180 |
Cholelithiasis | 12.32 | 9.32 | 171 | 161475 | 45335 | 64291751 |
Ileus | 12.25 | 9.32 | 99 | 161547 | 22867 | 64314219 |
Catheter site haemorrhage | 12.24 | 9.32 | 32 | 161614 | 4559 | 64332527 |
Intentional self-injury | 12.17 | 9.32 | 35 | 161611 | 29009 | 64308077 |
Iron deficiency anaemia | 12.03 | 9.32 | 95 | 161551 | 21794 | 64315292 |
Injury | 11.93 | 9.32 | 202 | 161444 | 55790 | 64281296 |
Rash | 11.92 | 9.32 | 1318 | 160328 | 457231 | 63879855 |
Coronary artery dissection | 11.91 | 9.32 | 13 | 161633 | 897 | 64336189 |
Blood pressure systolic abnormal | 11.89 | 9.32 | 5 | 161641 | 9937 | 64327149 |
Swollen tongue | 11.87 | 9.32 | 137 | 161509 | 34817 | 64302269 |
Joint stiffness | 11.76 | 9.32 | 38 | 161608 | 30366 | 64306720 |
Victim of chemical submission | 11.67 | 9.32 | 8 | 161638 | 292 | 64336794 |
Diarrhoea | 11.62 | 9.32 | 2019 | 159627 | 720685 | 63616401 |
Device difficult to use | 11.60 | 9.32 | 5 | 161641 | 9793 | 64327293 |
Poisoning deliberate | 11.57 | 9.32 | 10 | 161636 | 13448 | 64323638 |
Heparin-induced thrombocytopenia | 11.56 | 9.32 | 47 | 161599 | 8432 | 64328654 |
Injection site reaction | 11.55 | 9.32 | 69 | 161577 | 46595 | 64290491 |
Cystitis noninfective | 11.45 | 9.32 | 14 | 161632 | 1092 | 64335994 |
Granulocyte count decreased | 11.38 | 9.32 | 15 | 161631 | 1261 | 64335825 |
Cystic fibrosis | 11.35 | 9.32 | 26 | 161620 | 3408 | 64333678 |
Platelet transfusion | 11.34 | 9.32 | 18 | 161628 | 1793 | 64335293 |
Infection | 11.30 | 9.32 | 365 | 161281 | 184515 | 64152571 |
Foot deformity | 11.15 | 9.32 | 15 | 161631 | 16489 | 64320597 |
Allergy test positive | 11.07 | 9.32 | 9 | 161637 | 427 | 64336659 |
Tinea pedis | 10.91 | 9.32 | 19 | 161627 | 2042 | 64335044 |
Injection site erythema | 10.91 | 9.32 | 119 | 161527 | 70681 | 64266405 |
Nausea | 10.82 | 9.32 | 2178 | 159468 | 783622 | 63553464 |
Hypophagia | 10.82 | 9.32 | 149 | 161497 | 39438 | 64297648 |
Putamen haemorrhage | 10.80 | 9.32 | 9 | 161637 | 442 | 64336644 |
Ischaemic stroke | 10.75 | 9.32 | 37 | 161609 | 28998 | 64308088 |
Urine osmolarity decreased | 10.72 | 9.32 | 5 | 161641 | 85 | 64337001 |
Lymphopenia | 10.69 | 9.32 | 31 | 161615 | 25626 | 64311460 |
Cancer pain | 10.67 | 9.32 | 29 | 161617 | 4228 | 64332858 |
Substance abuse | 10.60 | 9.32 | 5 | 161641 | 9287 | 64327799 |
Wound secretion | 10.57 | 9.32 | 33 | 161613 | 5199 | 64331887 |
Catatonia | 10.55 | 9.32 | 3 | 161643 | 7617 | 64329469 |
Pneumothorax | 10.50 | 9.32 | 100 | 161546 | 24198 | 64312888 |
Hepatitis cholestatic | 10.49 | 9.32 | 9 | 161637 | 12146 | 64324940 |
Post procedural haemorrhage | 10.48 | 9.32 | 60 | 161586 | 12371 | 64324715 |
Lymphocyte percentage increased | 10.48 | 9.32 | 10 | 161636 | 588 | 64336498 |
Hypoparathyroidism | 10.46 | 9.32 | 12 | 161634 | 875 | 64336211 |
Amylase increased | 10.41 | 9.32 | 50 | 161596 | 9635 | 64327451 |
Reversible cerebral vasoconstriction syndrome | 10.39 | 9.32 | 20 | 161626 | 2322 | 64334764 |
Anal erosion | 10.39 | 9.32 | 4 | 161642 | 41 | 64337045 |
Supine hypertension | 10.34 | 9.32 | 8 | 161638 | 353 | 64336733 |
Peritonitis | 10.33 | 9.32 | 102 | 161544 | 24921 | 64312165 |
Palmar-plantar erythrodysaesthesia syndrome | 10.26 | 9.32 | 114 | 161532 | 28705 | 64308381 |
Hyperlipidaemia | 10.15 | 9.32 | 95 | 161551 | 22881 | 64314205 |
Restless arm syndrome | 10.14 | 9.32 | 4 | 161642 | 44 | 64337042 |
Dermatitis acneiform | 10.12 | 9.32 | 45 | 161601 | 8398 | 64328688 |
Hypokalaemia | 10.03 | 9.32 | 387 | 161259 | 121516 | 64215570 |
Cognitive disorder | 9.99 | 9.32 | 89 | 161557 | 54998 | 64282088 |
Hypersomnia | 9.99 | 9.32 | 84 | 161562 | 19633 | 64317453 |
Pityriasis lichenoides et varioliformis acuta | 9.98 | 9.32 | 4 | 161642 | 46 | 64337040 |
Tumour lysis syndrome | 9.94 | 9.32 | 83 | 161563 | 19357 | 64317729 |
Laboratory test abnormal | 9.89 | 9.32 | 98 | 161548 | 23965 | 64313121 |
Human ehrlichiosis | 9.89 | 9.32 | 8 | 161638 | 377 | 64336709 |
Lymphocyte count decreased | 9.86 | 9.32 | 150 | 161496 | 40549 | 64296537 |
VIIth nerve injury | 9.86 | 9.32 | 6 | 161640 | 178 | 64336908 |
Convulsions local | 9.83 | 9.32 | 4 | 161642 | 48 | 64337038 |
Stoma site cellulitis | 9.81 | 9.32 | 3 | 161643 | 14 | 64337072 |
Metabolic encephalopathy | 9.79 | 9.32 | 43 | 161603 | 7982 | 64329104 |
Nephrogenic anaemia | 9.72 | 9.32 | 24 | 161622 | 3301 | 64333785 |
Therapeutic hypothermia | 9.64 | 9.32 | 3 | 161643 | 15 | 64337071 |
PCO2 decreased | 9.63 | 9.32 | 22 | 161624 | 2880 | 64334206 |
Malignant melanoma | 9.58 | 9.32 | 11 | 161635 | 12953 | 64324133 |
PO2 increased | 9.58 | 9.32 | 15 | 161631 | 1477 | 64335609 |
Vertigo | 9.57 | 9.32 | 98 | 161548 | 58913 | 64278173 |
Gastritis | 9.54 | 9.32 | 155 | 161491 | 42463 | 64294623 |
Mean arterial pressure increased | 9.47 | 9.32 | 4 | 161642 | 53 | 64337033 |
Abdominal distension | 9.44 | 9.32 | 311 | 161335 | 95683 | 64241403 |
Malnutrition | 9.43 | 9.32 | 81 | 161565 | 19044 | 64318042 |
Bronchial hyperreactivity | 9.41 | 9.32 | 20 | 161626 | 2492 | 64334594 |
Eosinophil count increased | 9.33 | 9.32 | 64 | 161582 | 14048 | 64323038 |
Hypergeusia | 9.33 | 9.32 | 3 | 161643 | 17 | 64337069 |
None
Source | Code | Description |
---|---|---|
ATC | A02BA03 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
ATC | A02BA53 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
FDA MoA | N0000000151 | Histamine H2 Receptor Antagonists |
CHEBI has role | CHEBI:37961 | H2 receptor antagonists |
CHEBI has role | CHEBI:49201 | anti-ulcer drugs |
CHEBI has role | CHEBI:50183 | P450 inhibitors |
FDA EPC | N0000175784 | Histamine-2 Receptor Antagonist |
MeSH PA | D000897 | Anti-Ulcer Agents |
MeSH PA | D005765 | Gastrointestinal Agents |
MeSH PA | D018494 | Histamine Agents |
MeSH PA | D006633 | Histamine Antagonists |
MeSH PA | D006635 | Histamine H2 Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Heartburn | indication | 16331000 | |
Erosive esophagitis | indication | 40719004 | |
Duodenal ulcer disease | indication | 51868009 | DOID:1724 |
Zollinger-Ellison syndrome | indication | 53132006 | DOID:0050782 |
Peptic reflux disease | indication | 57643001 | |
Indigestion | indication | 162031009 | |
Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
Gastric ulcer | indication | 397825006 | DOID:10808 |
Dyspepsia Prevention | indication | ||
Maintenance of Healing Duodenal Ulcer | indication | ||
Heartburn Prevention | indication | ||
Upper gastrointestinal hemorrhage | off-label use | 37372002 | |
Prevention of Stress Ulcer | off-label use | ||
Constipation | contraindication | 14760008 | DOID:2089 |
Sarcoidosis | contraindication | 31541009 | DOID:11335 |
Dehydration | contraindication | 34095006 | |
Diarrhea | contraindication | 62315008 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Kidney stone | contraindication | 95570007 | |
Impaired renal function disorder | contraindication | 197663003 | |
Osteolysis | contraindication | 203522001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Malignant tumor of stomach | contraindication | 363349007 | DOID:10534 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.84 | acidic |
pKa2 | 12.0 | acidic |
pKa3 | 6.97 | Basic |
pKa4 | 6.37 | Basic |
pKa5 | 2.56 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
26.6MG;800MG | DUEXIS | HORIZON | N022519 | April 23, 2011 | RX | TABLET | ORAL | 8067451 | July 18, 2026 | RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS |
26.6MG;800MG | DUEXIS | HORIZON | N022519 | April 23, 2011 | RX | TABLET | ORAL | 8501228 | July 18, 2026 | RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Histamine H2 receptor | GPCR | ANTAGONIST | Kd | 7.93 | WOMBAT-PK | CHEMBL | |||
Carbonic anhydrase 2 | Enzyme | Ki | 7.24 | CHEMBL | |||||
Carbonic anhydrase 1 | Enzyme | Ki | 6.04 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 6.03 | CHEMBL | |||||
Carbonic anhydrase 9 | Enzyme | Ki | 6.90 | CHEMBL | |||||
Carbonic anhydrase 12 | Enzyme | Ki | 7.34 | CHEMBL | |||||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 5.84 | CHEMBL | |||||
Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 5.27 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 8.52 | CHEMBL | |||||
Carbonic anhydrase 6 | Enzyme | Ki | 7.01 | CHEMBL | |||||
Carbonic anhydrase 14 | Enzyme | Ki | 6.17 | CHEMBL | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 6.77 | CHEMBL | |||||
Solute carrier family 22 member 2 | Transporter | IC50 | 4.44 | CHEMBL | |||||
Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 6.12 | CHEMBL | |||||
Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 4.44 | CHEMBL | |||||
Heat shock protein HSP 90-alpha | Cytosolic other | IC50 | 5.30 | WOMBAT-PK | |||||
Solute carrier family 22 member 3 | Transporter | IC50 | 4.97 | CHEMBL | |||||
Histamine H2 receptor | GPCR | Kd | 7 | CHEMBL |
ID | Source |
---|---|
4017970 | VUID |
N0000146320 | NUI |
D00318 | KEGG_DRUG |
4017970 | VANDF |
C0015620 | UMLSCUI |
CHEBI:4975 | CHEBI |
FO9 | PDB_CHEM_ID |
CHEMBL902 | ChEMBL_ID |
DB00927 | DRUGBANK_ID |
D015738 | MESH_DESCRIPTOR_UI |
5353622 | PUBCHEM_CID |
7074 | IUPHAR_LIGAND_ID |
5217 | INN_ID |
5QZO15J2Z8 | UNII |
4278 | RXNORM |
41331 | MMSL |
4713 | MMSL |
d00141 | MMSL |
003417 | NDDF |
387211002 | SNOMEDCT_US |
39128000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Ibuprofen and famotidine | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-8107 | TABLET, FILM COATED | 26.60 mg | ORAL | ANDA | 28 sections |
Good Sense Dual Action Complete | HUMAN OTC DRUG LABEL | 3 | 0113-0032 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
good sense acid reducer | HUMAN OTC DRUG LABEL | 1 | 0113-0141 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
Good Sense Acid Reducer | HUMAN OTC DRUG LABEL | 1 | 0113-0194 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
Good Sense Acid Reducer | HUMAN OTC DRUG LABEL | 1 | 0113-0194 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
basic care acid reducer | HUMAN OTC DRUG LABEL | 1 | 0113-7141 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
Basic Care famotidine | HUMAN OTC DRUG LABEL | 1 | 0113-7194 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 14 sections |
basic care dual action complete | HUMAN OTC DRUG LABEL | 3 | 0113-7321 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0172-5728 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 25 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0172-5729 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 25 sections |
Pepcid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-4420 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 25 sections |
Pepcid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-4440 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 25 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-5197 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 22 sections |
Acid ControllerOriginal Strength | HUMAN OTC DRUG LABEL | 1 | 0363-0141 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
Acid ControllerOriginal Strength | HUMAN OTC DRUG LABEL | 1 | 0363-0141 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 15 sections |
Acid Reducer Complete | HUMAN OTC DRUG LABEL | 3 | 0363-0511 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
Acid Controller | HUMAN OTC DRUG LABEL | 1 | 0363-0701 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
Acid Controller | HUMAN OTC DRUG LABEL | 1 | 0363-0701 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
Acid Reducer Complete | HUMAN OTC DRUG LABEL | 3 | 0363-0713 | TABLET, CHEWABLE | 10 mg | ORAL | ANDA | 15 sections |
acid controller | HUMAN OTC DRUG LABEL | 1 | 0363-1203 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
Famotidine | Human OTC Drug Label | 1 | 0363-1899 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 16 sections |
Famotidine | Human OTC Drug Label | 1 | 0363-4400 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 16 sections |
Famotidine | Human OTC Drug Label | 1 | 0363-5300 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 16 sections |
Rugby Famotidine | HUMAN OTC DRUG LABEL | 1 | 0536-1298 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 15 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-4582 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 20 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8301 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 20 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6021 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6022 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
Famotidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6023 | INJECTION | 10 mg | INTRAVENOUS | ANDA | 22 sections |
heartburn relieforiginal strength | HUMAN OTC DRUG LABEL | 1 | 0904-5529 | TABLET | 10 mg | ORAL | ANDA | 15 sections |